Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

CYP2D6 Rabbit Polyclonal Antibody

Product Specifications

Background

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize as many as 25% of commonly prescribed drugs. Its substrates include antidepressants, antipsychotics, analgesics and antitussives, beta adrenergic blocking agents, antiarrythmics and antiemetics. The gene is highly polymorphic in the human population; certain alleles result in the poor metabolizer phenotype, characterized by a decreased ability to metabolize the enzyme's substrates. Some individuals with the poor metabolizer phenotype have no functional protein since they carry 2 null alleles whereas in other individuals the gene is absent. This gene can vary incatalytic activity:RH + reduced flavoprotein + O (2) = ROH + oxidized flavoprotein + H (2) O., cofactor:Heme group., function:Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants., induction:By pregnancy., online information:CYP2D6 alleles, online information:CYP2D6 entry, polymorphism:Allele CYP2D6*7 was also known as CYP2D6E, allele CYP2D6*9 as CYP2D6C, allele CYP2D6*10 as CYP2D6J, allele CYP2D6*17 as CYP2D6Z., polymorphism:Genetic variations in CYP2D6 are the cause of poor drug metabolism CYP2D6-related [MIM:608902]. The CYP2D6 gene is highly polymorphic. CYP2D6 activity ranges widely within a population comprising ultrarapid (UM), extensive (EM), intermediate (IM) and poor (PM) metabolizer phenotypes. UM and PM are those most at risk for treatment failure or dose-dependent drug toxicity, respectively. Of the Caucasian populations of Europe and North America, 5%-10% are of the PM phenotype and are unable to metabolize the antihypersensitive drug debrisoquine and numerous other drugs., polymorphism:Isozymes CYP2D6.45 (Lys-155, Cys-296 and Thr-486) and CYP2D6.46 (His-26, Lys-155, Cys-296 and Thr-486) are functional., similarity:Belongs to the cytochrome P450 family.

Product Name Alternative

CYP2D6; CYP2DL1; Cytochrome P450 2D6; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase

Gene Name

CYP2D6

Gene ID

1565

Swiss Prot

P10635

Host

Rabbit

Reactivity

Human

Clonality

Polyclonal

Conjugation

Unconjugated

Applications

WB, IHC, ICC/IF, ELISA

Field of Research

Drug metabolism

Purification

Affinity purification

Dilution

WB 1:500-1:2000, IHC 1:100-1:300, ICC/IF 1:50-1:200, ELISA 1:5000-1:20000

Form

Liquid

Buffer

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N.

Modification

Unmodified

Molecular Weight

55kDa

Storage Conditions

Store at 4°C short term. Aliquot and store at -20°C for 12 months. Avoid freeze/thaw cycles.

Isotype

IgG

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Human CD47 Affinity Purified Polyclonal Ab
AF4670-SP 25 µg

Human CD47 Affinity Purified Polyclonal Ab

Ask
View Details
Ganoderol B
278484-01 1 mg

Ganoderol B

Ask
View Details
Ganoderol B
278484-02 2 mg

Ganoderol B

Ask
View Details
Ganoderol B
278484-03 5 mg

Ganoderol B

Ask
View Details
Ganoderol B
278484-04 10 mg

Ganoderol B

Ask
View Details
Ganoderol B
278484-05 25 mg

Ganoderol B

Ask
View Details